Compare OVBC & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVBC | MCRB |
|---|---|---|
| Founded | 1872 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.3M | 162.7M |
| IPO Year | N/A | 2015 |
| Metric | OVBC | MCRB |
|---|---|---|
| Price | $41.53 | $15.58 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | 15.9K | ★ 248.7K |
| Earning Date | 01-27-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | ★ 22.03 | N/A |
| EPS | ★ 3.01 | 0.62 |
| Revenue | ★ $64,211,000.00 | $351,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $13.80 | $24.94 |
| Revenue Growth | ★ 11.98 | N/A |
| 52 Week Low | $21.86 | $6.53 |
| 52 Week High | $42.00 | $29.98 |
| Indicator | OVBC | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 73.04 | 42.68 |
| Support Level | $38.36 | $15.68 |
| Resistance Level | $42.00 | $17.90 |
| Average True Range (ATR) | 1.01 | 1.12 |
| MACD | 0.06 | -0.22 |
| Stochastic Oscillator | 90.48 | 4.51 |
Ohio Valley Banc Corporation is a financial holding company. The bank is a full-service financial institution offering a blend of commercial and consumer banking services within Southeastern Ohio as well as western West Virginia. The banking services offered by the bank include the acceptance of deposits in checking, savings, time and money market accounts; the making and servicing of personal, commercial, and student loans; and the making of construction and real estate loans. It also offers individual retirement accounts, safe deposit boxes, wire transfers and other standard banking products and services.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.